Key terms
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TVTX news
May 07
11:57pm ET
Buy Rating Affirmed for Travere Therapeutics on Strong Filspari Sales and Favorable Regulatory Prospects
May 07
12:30pm ET
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Travere Therapeutics (TVTX)
May 07
12:20pm ET
Analysts Offer Insights on Healthcare Companies: Caliber Imaging & Diagnostic (OtherLCDX) and Travere Therapeutics (TVTX)
May 07
9:00am ET
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
May 07
8:16am ET
Travere Therapeutics (TVTX) Gets a Hold from Stifel Nicolaus
May 07
7:51am ET
Buy Rating Affirmed for Travere Therapeutics on Robust Drug Sales and Promising Market Expansion
May 07
7:42am ET
Barclays Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)
May 06
4:08pm ET
Travere Therapeutics reports Q1 EPS (1.51) , consensus (99c)
Apr 26
7:50am ET
Travere Therapeutics (TVTX) Receives a Hold from Piper Sandler
Apr 26
2:17am ET
Buy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US Prospects
Apr 25
7:16am ET
Buy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue Projections
Apr 25
5:50am ET
Analysts Conflicted on These Healthcare Names: Travere Therapeutics (TVTX), Humana (HUM) and Merck & Company (MRK)
Apr 24
12:35pm ET
FILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere Therapeutics
Apr 24
12:27pm ET
Travere Therapeutics price target raised to $19 from $17 at H.C. Wainwright
Apr 24
7:10am ET
Travere Therapeutics, CSL Vifor announce EC approves FILSPARI
Apr 24
5:21am ET
Travere Therapeutics, CSL Vifor announce EC approval for Filspari
Mar 27
9:24am ET
Travere downgraded to Neutral at Guggenheim on smaller role in IgAN space
Mar 27
6:43am ET
Travere Therapeutics downgraded to Neutral from Buy at Guggenheim
Mar 13
9:55am ET
Buy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlook
Mar 11
7:42am ET
Travere Therapeutics submits sNDA for FILSPARI for IgAN
Feb 27
11:50pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX)
Feb 24
9:59am ET
Travere’s Sparsentan Nears European Market Breakthrough
Feb 23
10:35am ET
Buy Rating Affirmed: Expanding Market Potential for Travere Therapeutics’ Sparsentan
Feb 23
10:23am ET
Travere Therapeutics price target lowered to $17 from $20 at H.C. Wainwright
Feb 23
7:09am ET
Travere , CSL Vifor announce Sparsentan received positive CHMP opinion
Feb 23
5:14am ET
Travere Therapeutics, CSL Vifor get CHMP recommendation for sparsentan approval
Feb 21
1:01am ET
New Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?
Feb 18
11:47pm ET
Buy Rating Affirmed for Travere Therapeutics Amidst Strong Filspari Launch and Promising Growth Prospects
Feb 16
5:40pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Travere Therapeutics (TVTX) and 10x Genomics (TXG)
Feb 16
5:23pm ET
Travere Therapeutics price target raised to $14 from $10 at Citi
Feb 16
8:39am ET
Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)
No recent press releases are available for TVTX
TVTX Financials
Key terms
Ad Feedback
TVTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TVTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
